Cerus expects 14% jump in 2025 topline, guides 2026

[Fourth Quarter Q4 Profits Stock Trading Chart 3D Background]

* Cerus (CERS [https://seekingalpha.com/symbol/CERS]) announced [https://seekingalpha.com/pr/20359863-cerus-corporation-announces-preliminary-fourth-quarter-and-full-year-2025-product-revenue-and] preliminary unaudited product revenue results for Q4 and FY, showing strong growth in its blood safety products, particularly the INTERCEPT Fibrinogen Complex (IFC)
* Q4 product revenue is expected to touch $57.8M, up 14% Y/Y. IFC contributed $4.2M in this period, reflecting about 40% Y/Y growth.
* FY product revenue is expected to be $206.1M, 14% growth vs. prior year. IFC accounted for $16.7M, roughly 80% growth Y/Y.
* The company expects FY 2026 product revenue to be in the range of $224M to $228M, representing Y/Y growth of 9%-11% compared to preliminary unaudited 2025 product revenue. Included in the 2026 guidance range is expected full-year 2026 IFC revenue of $20 million to $22 million, representing year-over-year growth of approximately 20% to 30% from 2025.
* The stock price rose ~2% on Monday during pre-market hours of trading.

MORE ON CERUS

* Cerus: IFC Growth And RBC Optionality [https://seekingalpha.com/article/4846986-cerus-stock-ifc-growth-rbc-optionality-reasonable-valuation-buy]
* Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4839855-cerus-corporation-cers-q3-2025-earnings-call-transcript]
* Cerus raises 2025 product revenue guidance to $202M-$204M while accelerating IFC kit transition [https://seekingalpha.com/news/4518156-cerus-raises-2025-product-revenue-guidance-to-202m-204m-while-accelerating-ifc-kit-transition]
* Seeking Alpha’s Quant Rating on Cerus [https://seekingalpha.com/symbol/CERS/ratings/quant-ratings]
* Historical earnings data for Cerus [https://seekingalpha.com/symbol/CERS/earnings]